Drug pricing should be near top of agenda at Trump-Takaichi meeting

President Donald Trump will soon host Japanese Prime Minister Sanae Takaichi at the White House, where the two leaders will ...
BioSpaceOpinion

Opinion: Japan’s Drug Prices Are Creating Problems for Washington and Tokyo Alike

If they work together to implement drug pricing reforms in Japan, it would help revive the island nation’s stagnating life ...
High Times

Japanese Ditching Dangerous Drugs for Pot, But Police Don’t Like It

Unlike Tom Waits, drugs are not big in Japan. The Japanese have some of the lowest rates of drug use of any Western-style democracy with a powerful economy. How low? At one point in the mid-1980s, ...
Yahoo Finance

Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan

Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well ...

Novo Nordisk Seeking to Expand Weight-Loss Drugs Access in Japan

Novo Nordisk A/S is seeking to broaden access to obesity treatments in Japan by targeting patients willing to pay ...
Nasdaq

Rhythm Pharmaceuticals Receives Orphan Drug Designation in Japan for Setmelanotide in Acquired Hypothalamic Obesity Treatment

Rhythm Pharmaceuticals, Inc. has announced that it received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for setmelanotide, a treatment aimed at acquired hypothalamic ...
Zacks Investment Research on MSN

GSK's Risvutatug Rezetecan gets Japan orphan drug tag for lung cancer

GSK plc GSK announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation (ODD) to ...
Seeking Alpha

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments ...